6-Gingerol

Catalog No.S3836 Batch:S383602

Technical Data

Formula	C₁₇H₂₆O₄
Molecular Weight	294.39	CAS No.	23513-14-6
Solubility (25°C)*	In vitro	DMSO	60 mg/mL (203.81 mM)
		Ethanol	60 mg/mL (203.81 mM)

* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	6-Gingerol is the active constituent of fresh ginger known to exhibit a variety of biological activities including anticancer, anti-inflammation, and anti-oxidation.
In vitro	6-gingerol treatment significantly reduces the cell viability of human colon cancer cell, LoVo, in a dose-dependent manner. 6-gingerol induces significant G2/M phase arrest and has slight influence on sub-G1 phase in LoVo cells. Levels of cyclin A, cyclin B1, and CDK1 are diminished; in contrast, levels of the negative cell cycle regulators p27Kip1 and p21Cip1 are increased in response to 6-gingerol treatment. In addition, 6-gingerol treatment elevates intracellular reactive oxygen species (ROS) and phosphorylation level of p53. 6-gingerol is effective in suppressing the transformation, hyperproliferation, and inflammatory processes that initiate and promote carcinogenesis, as well as the later steps of carcinogenesis, namely, angiogenesis and metastasis^[1]. 6-gingerol has direct cytotoxic effects on cultures of tumor cells, such as colorectal cancer cells, HL-60 cells and breast cancer cells^[2].
In vivo	6-gingerol inhibits tumor growth in several types of murine tumors, such as B16F1 melanomas, Renca renal cell carcinomas and CT26 colon carcinomas, established by inoculating tumor cells on the flanks of mice, although it does not lead to complete eradication of the tumors. 6-gingerol treatment of tumor-bearing mice causes massive infiltration of CD4 and CD8 T-cells and B220+ B-cells, but reduces the number of CD4+Foxp3+ regulatory T-cells. The CD8 tumor-infiltrating T lymphocytes in 6-gingerol-treated mice strongly express IFN-γ, a marker of activation of CTL CD107a cells, and chemokine receptors that are expressed on TH1 cells, such as CXCR3 and CCR5^[2].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines Colon cancer cell line LoVo Concentrations 1, 5, 10, and 15 μg/mL Incubation Time 24 h or 48 h Method Colon cancer cell line LoVo is maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% v/v fetal bovine serum, 1% nonessential amino acid, 1% L-glutamine, and 100 μg/mL penicillin/streptomycin at 37°C in a humidified atmosphere with 5% CO2. Cells are seeded in 10 cm Petri dishes at an initial density of 2×10⁵ cells/mL and grown to approximately 80% confluence. Then, the cells are collected for the subsequent analyses including cell viability, flow cytometric analysis, and immunoblotting analysis. For 6-gingerol treatments, cells are starved for 24 hours (h) in serum-free DMEM and then incubated with 6-gingerol at a series of concentrations in serum-free DMEM (1, 5, 10, and 15 μg/mL) for 24 h or 48 h.
Animal Study:^{^[2]}	Animal Models Female Balb/c and C57BL/6 mice (Mice areinoculated with 3.0×10⁵ CT26 cells, 7×10⁵ Renca cells [Balb/c], or 2.5×10⁵ B16F1 cells [C57BL/6] in the left flank） Dosages 3 μg/ml Administration p.o.

Cell Assay:^{^[1]}

Cell lines
Colon cancer cell line LoVo
Concentrations
1, 5, 10, and 15 μg/mL
Incubation Time
24 h or 48 h
Method
Colon cancer cell line LoVo is maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% v/v fetal bovine serum, 1% nonessential amino acid, 1% L-glutamine, and 100 μg/mL penicillin/streptomycin at 37°C in a humidified atmosphere with 5% CO2. Cells are seeded in 10 cm Petri dishes at an initial density of 2×10⁵ cells/mL and grown to approximately 80% confluence. Then, the cells are collected for the subsequent analyses including cell viability, flow cytometric analysis, and immunoblotting analysis. For 6-gingerol treatments, cells are starved for 24 hours (h) in serum-free DMEM and then incubated with 6-gingerol at a series of concentrations in serum-free DMEM (1, 5, 10, and 15 μg/mL) for 24 h or 48 h.

Animal Study:^{^[2]}

Animal Models
Female Balb/c and C57BL/6 mice (Mice areinoculated with 3.0×10⁵ CT26 cells, 7×10⁵ Renca cells [Balb/c], or 2.5×10⁵ B16F1 cells [C57BL/6] in the left flank）
Dosages
3 μg/ml
Administration
p.o.

References

Selleck's 6-Gingerol has been cited by 3 publications

6-Gingerol Improves In Vitro Porcine Embryo Development by Reducing Oxidative Stress [ Animals (Basel), 2023, 13(8)1315]	PubMed: 37106877
6-Gingerol suppresses tumor cell metastasis by increasing YAPser127 phosphorylation in renal cell carcinoma [ J Biochem Mol Toxicol, 2020, e22609]	PubMed: 32926756
6-Gingerol induces cell-cycle G1-phase arrest through AKT-GSK 3β-cyclin D1 pathway in renal-cell carcinoma. [ Cancer Chemother Pharmacol, 2020, 85(2):379-390]	PubMed: 31832810

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.